Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cortivazol
- Development stage
- Phase 4
- Lead developer
- Nordic Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intraarticular, Periarticular, Epidural
01
Overview
Cortivazol is a synthetic glucocorticoid classified as a high-affinity agonist of the glucocorticoid receptor. It is a small molecule steroid with potent anti-inflammatory and immunosuppressive properties, used primarily for the treatment of musculoskeletal and joint disorders, often administered by intra-articular, periarticular, or epidural injection. Its mechanism involves binding to and activating the glucocorticoid receptor, leading to modulation of gene expression that results in anti-inflammatory and immunosuppressive effects. Cortivazol has been investigated for use in cluster headache and has demonstrated activity even in dexamethasone-resistant cells due to its unique structure[1][2][4][5][6][8].
- Brand names
- AlacortAltimIdaltimDilaster
- Other names
- Cortivazolum
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on cortivazol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cortivazol.